Publication:
Risk of Secondary Progressive Multiple Sclerosis: A Longitudinal Study

dc.authorscopusid57213638007
dc.authorscopusid24391158100
dc.authorscopusid55053678000
dc.authorscopusid57201596736
dc.authorscopusid7005165969
dc.authorscopusid7103277065
dc.authorscopusid57201788612
dc.contributor.authorFambiatos, A.
dc.contributor.authorJokubaitis, V.
dc.contributor.authorHoráková, D.
dc.contributor.authorKubala Havrdová, E.
dc.contributor.authorTrojano, M.
dc.contributor.authorPrat, A.
dc.contributor.authorGirard, M.
dc.date.accessioned2020-06-21T12:26:11Z
dc.date.available2020-06-21T12:26:11Z
dc.date.issued2020
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Fambiatos] Adam, Department of Medicine, Melbourne, VIC, Australia; [Jokubaitis] Vilija G., Monash University, Melbourne, VIC, Australia, The Alfred, Melbourne, VIC, Australia; [Horáková] Dana, Department of Neurology and Center of Clinical Neuroscience, Všeobecná Fakultní Nemocnice v Praze, Prague, Czech Republic; [Kubala Havrdová] Eva Kubala, Department of Neurology and Center of Clinical Neuroscience, Všeobecná Fakultní Nemocnice v Praze, Prague, Czech Republic; [Trojano] Maria, Department of Basic Medical Sciences, Università degli studi di Bari Aldo Moro, Bari, BA, Italy; [Prat] Alexandre, Hôpital Notre-Dame, Montreal, QC, Canada, Centre Hospitalier de L'Université de Montréal, Montreal, QC, Canada; [Girard] Marc, Hôpital Notre-Dame, Montreal, QC, Canada, Centre Hospitalier de L'Université de Montréal, Montreal, QC, Canada; [Duquette] Pierre Pascal, Hôpital Notre-Dame, Montreal, QC, Canada, Centre Hospitalier de L'Université de Montréal, Montreal, QC, Canada; [Lugaresi] Alessandra, Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy, Dipartimento di Scienze Biomediche e Neuromotorie, Alma Mater Studiorum Università di Bologna, Bologna, BO, Italy; [Izquierdo] Guillermo Ayuso, Hospital Universitario Virgen Macarena, Sevilla, Spain; [Grand'Maison] François, Neuro Rive-Sud, Quebec, QC, Canada; [Grammond] Pierre, CISSS de Chaudière-Appalache, Centre-Hospitalier, Levis, Canada; [Sola] Patrizia, Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy; [Ferraro] Diana, Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy; [Alroughani] Raed A., Al-Amiri Hospital, Safat, Kuwait; [Terzi] Murat, Faculty of Medicine, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Hupperts] Raymond M.M., Zuyderland, Sittard-Geleen, Limburg, Netherlands; [Boz] Cavit, TU Medical Faculty, Karadeniz Teknik University Farabi Hospital, Trabzon, Turkey; [Lechner-Scott] Jeannette S., School of Medicine and Public Health, Callaghan, NSW, Australia, Department of Neurology, John Hunter Hospital, Newcastle, NSW, Australia; [Pucci] Eugenio, UOC Neurologia, Macerata, Italy; [Bergamaschi] Roberto, IRCCS Fondazione Mondino, Pavia, PV, Italy; [van Pesch] Vincent, Cliniques Universitaires Saint-Luc, Brussels, BRU, Belgium; [Özakbaş] Serkan, Dokuz Eylül Üniversitesi, Izmir, Turkey; [Granella] Franco, Department of Medicine and Surgery, Università di Parma, Parma, PR, Italy; [Türkoǧlu] Recai, Sultan 2.Abdülhamid Han Eğitim ve Araştirma Hastanesi, Uskudar, Istanbul, Turkey; [Iuliano] Gerardo, Ospedali Riuniti di Salerno, Salerno, Italy; [Spitaleri] Daniele Litterio A., Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, AV, Italy; [McCombe] Pamela A., The University of Queensland, Brisbane, QLD, Australia, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia; [Solaro] Claudio Marcello, Ospedale P.A. Micone, Genoa, Italy; [Slee] Mark, Flinders University, Adelaide, SA, Australia; [Ampapa] Radek, Nemocnice Jihlava, Jihlava, Czech Republic; [Soysal] Aysun, Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Istanbul, Turkey; [Petersen] Thor K., Aarhus Universitetshospital, Aarhus, Midtjylland, Denmark; [Sánchez-Menoyo] José Luis, Hospital de Galdakao, Galdakao, Biscay, Spain; [Verheul] Freek A.M., Groene Hart Hospital, Gouda, Netherlands; [Prevost] Julie, CSSS Saint-Jérôme, Saint-Jerome, QC, Canada; [Sidhom] Youssef, Department of Neurology, Université de Tunis El Manar, Hôpital Razi, Manouba, Tunisia; [van Wijmeersch] Bart, Universiteit Hasselt, Hasselt, VLI, Belgium; [Vucic] Steve, Westmead Hospital, Sydney, NSW, Australia; [Cristiano] Edgardo, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; [Saladino] Maria Laura, Instituto de Neurociencias Buenos Aires, Buenos Aires, Argentina; [Deri] Norma Haydee, Hospital General de Agudos Juan Fernandez, Buenos Aires, Argentina; [Barnett] Michael H., The University of Sydney, Sydney, NSW, Australia; [Olascoaga] Javier Sebastián, Osakidetza, Donostia University Hospital, Donostia-San Sebastian, Guipuzcoa, Spain; [Moore] Fraser G.A., Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC, Canada; [Skibina] Olga G., The Alfred, Melbourne, VIC, Australia; [Gray] Orla M., Belfast Health and Social Care Trust, Belfast, Antrim, Northern Ireland, United Kingdom; [Fragoso] Yára Dadalti, Universidade Metropolitana de Santos, Santos, SP, Brazil; [Yamout] Bassem I., American University of Beirut, Beirut, Beirut Governorate, Lebanon; [Shaw] Cameron P., Geelong Hospital, Geelong, VIC, Australia; [Singhal] Bhim Sen, Bombay Hospital and Medical Research Centre, Mumbai, MH, India; [Shuey] Neil H., St. Vincent's Hospital Melbourne, Fitzroy, VIC, Australia; [Hodgkinson] Suzanne J., Liverpool Hospital, Liverpool, NSW, Australia; [Altintaş] Ayşe, İstanbul University-Cerrahpaşa Cerrahpaşa Faculty of Medicine, Istanbul, Turkey; [Al-Harbi] Talal M., King Fahad Specialist Hospital-Dammam, Dammam, Ash Sharqiyah, Saudi Arabia; [Csépány] Tünde, Department of Neurology, Általános Orvostudományi Kar, Debrecen, Hajdu-Bihar, Hungary; [Taylor] Bruce V.M., Royal Hobart Hospital, Hobart, TS, Australia; [Hughes] Jordana, Department of Medicine, Melbourne, VIC, Australia; [Jun] Jae-kwan, Department of Medicine, Melbourne, VIC, Australia; [van der Walt] Anneke, Monash University, Melbourne, VIC, Australia, The Alfred, Melbourne, VIC, Australia; [Spelman] Tim D., Monash University, Melbourne, VIC, Australia; [Butzkueven] Helmut, Monash University, Melbourne, VIC, Australia, The Alfred, Melbourne, VIC, Australia, Department of Neurology, Box Hill Hospital, Sydney, VIC, Australia; [Kalincik] Tomas, Department of Medicine, Melbourne, VIC, Australia, Department of Neurology, Royal Melbourne Hospital, Melbourne, VIC, Australia, L4 Centre, Royal Melbourne Hospital, Melbourne, VIC, Australiaen_US
dc.description.abstractBackground: The risk factors for conversion from relapsing-remitting to secondary progressive multiple sclerosis remain highly contested. Objective: The aim of this study was to determine the demographic, clinical and paraclinical features that influence the risk of conversion to secondary progressive multiple sclerosis. Methods: Patients with adult-onset relapsing–remitting multiple sclerosis and at least four recorded disability scores were selected from MSBase, a global observational cohort. The risk of conversion to objectively defined secondary progressive multiple sclerosis was evaluated at multiple time points per patient using multivariable marginal Cox regression models. Sensitivity analyses were performed. Results: A total of 15,717 patients were included in the primary analysis. Older age (hazard ratio (HR) = 1.02, p < 0.001), longer disease duration (HR = 1.01, p = 0.038), a higher Expanded Disability Status Scale score (HR = 1.30, p < 0.001), more rapid disability trajectory (HR = 2.82, p < 0.001) and greater number of relapses in the previous year (HR = 1.07, p = 0.010) were independently associated with an increased risk of secondary progressive multiple sclerosis. Improving disability (HR = 0.62, p = 0.039) and disease-modifying therapy exposure (HR = 0.71, p = 0.007) were associated with a lower risk. Recent cerebral magnetic resonance imaging activity, evidence of spinal cord lesions and oligoclonal bands in the cerebrospinal fluid were not associated with the risk of conversion. Conclusion: Risk of secondary progressive multiple sclerosis increases with age, duration of illness and worsening disability and decreases with improving disability. Therapy may delay the onset of secondary progression. © The Author(s), 2019.en_US
dc.identifier.doi10.1177/1352458519868990
dc.identifier.endpage90en_US
dc.identifier.issn1352-4585
dc.identifier.issn1477-0970
dc.identifier.issue1en_US
dc.identifier.pmid31397221
dc.identifier.scopus2-s2.0-85071005910
dc.identifier.scopusqualityQ1
dc.identifier.startpage79en_US
dc.identifier.urihttps://doi.org/10.1177/1352458519868990
dc.identifier.volume26en_US
dc.identifier.wosWOS:000481049900001
dc.identifier.wosqualityQ1
dc.language.isoenen_US
dc.publisherSAGE Publications Ltd info@sagepub.co.uken_US
dc.relation.ispartofMultiple Sclerosis Journalen_US
dc.relation.journalMultiple Sclerosis Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDisease Modifying Therapiesen_US
dc.subjectMultiple Sclerosisen_US
dc.subjectPredictionen_US
dc.subjectPrognosticsen_US
dc.subjectSPMSen_US
dc.titleRisk of Secondary Progressive Multiple Sclerosis: A Longitudinal Studyen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files